Abbott Laboratories announced that its next‑generation Ultreon 3.0 software has received U.S. Food and Drug Administration clearance and a CE Mark, allowing the company to offer a single, AI‑powered platform that combines optical coherence tomography with automated insights to guide percutaneous coronary intervention procedures.
The Ultreon 3.0 platform builds on the 2021 FDA clearance of Ultreon 2.0, adding advanced artificial‑intelligence capabilities that improve image interpretation and procedural decision‑making. The new software is designed to streamline the PCI workflow, reduce contrast use, and provide real‑time guidance that can accelerate treatment and improve patient outcomes.
Abbott’s approval aligns with its broader strategy of leveraging technology and AI to enhance cardiovascular care. The PCI market, which sees more than 600,000 procedures annually in the United States and 885,000 in Europe, represents a significant growth opportunity for Abbott’s medical‑device division.
"Abbott’s Ultreon 3.0 offers a single, AI‑driven platform that quickly and easily captures the images physicians need to fully understand the size and angle of the blockage, and create an actionable plan to help the patient. Every second and every decision matters when treating patients who have blockages in their coronary arteries, and Ultreon 3.0 enables faster, more informed clinical choices that can have a real impact on patients," said David M. Leistner, interventional cardiologist at the Clinic for Cardiology and Angiology, Charité Campus Benjamin‑Franklin.
"Complemented by our leading coronary portfolio, Ultreon 3.0 makes OCT imaging more intuitive and powerful for physicians, reimagining imaging into a tool for precision‑guided intervention before and after procedures," added Ethan Korngold, chief medical officer of Abbott’s vascular business.
"Ultreon 3.0 represents a pivotal step forward in how we treat and ultimately care for our patients. This next‑generation platform, combining imaging and AI, doesn’t just improve upon existing technology — it leapfrogs it. By delivering greater clarity, speed, and clinical insight, Ultreon 3.0 accelerates the path to more confident clinician decision making and transformative patient care," said Evan Shlofmitz, interventional cardiologist at St. Francis Hospital and Health Center.
The clearance positions Abbott to capture a larger share of the PCI market and supports its ongoing investment in AI‑driven diagnostics. While no immediate market reaction data were identified, the approval is expected to strengthen Abbott’s competitive stance and provide a new revenue stream within its high‑growth medical‑device segment.
revised_sentiment_rating
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.